Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Big Pharma walks away from gene-therapy biotech

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 02, 2023 1:22pm

234 Views

Post# 35477264

RE:RE:Big Pharma walks away from gene-therapy biotech

In December 2022 Quentin posted the following " My point is, whilst we wait for more Phase II data, the field is moving... away from chemo + Pela + CPI, to Gene edited cures. What do you think the better investment is ?" The response to Quentin's question became very evident then and even more evident today with Takeda walking away from it gene therapy investments.....

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing